The Global Fund is working to increase access to all the needed World Health Organization-recommended antimalarial medicines and formulations at the optimum price while simultaneously maintaining a sustainable competitive market. We have entered into framework agreements with a number of manufacturers to ensure prices and availability, based on anticipated market demand.
Documents related to our strategy, past tenders and reference prices are available for download here.
The Private Sector Co-payment Mechanism is a financing model used by the Global Fund to expand access to quality-assured artemisinin-based combination therapies (ACTs) through private sector distribution channels. The mechanism is well suited for countries where the private retail sector is a major provider of antimalarial medicines. The mechanism operates in six countries.
The Private Sector Co-payment Mechanism, along with its predecessor the Affordable Medicines Facility - malaria (AMFm), has demonstrated significant results in terms of lowering retail prices to patients and increasing access to quality-assured ACTs, the most effective antimalarial medicines available today. The model leverages Global Fund-negotiated ACT prices and further reduces the price to pharmaceutical importers in participating countries through a co-payment made by the Global Fund directly to manufacturers on their behalf. Country-led supporting interventions, such as large-scale mass communications around treatment seeking for malaria, are instrumental in rapid and large changes in price, availability and market share of quality-assured ACTs.
Several key actors – including implementing partners, national governments, ACT manufacturers, Local Fund Agents and participating pharmaceutical importers – work together to enable the co-payment mechanism to achieve its objectives.
Reference documents are available for download.